11
Participants
Start Date
December 8, 2020
Primary Completion Date
March 28, 2023
Study Completion Date
March 28, 2023
Mana 312
"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
Memorial Sloan Kettering Cancer Center, New York
Northside Hospital - Atlanta, Atlanta
Tennessee Oncology, Nashville
Vanderbilt - Ingram Cancer Center, Nashville
University of Kansas Cancer Center, Kansas City
Texas Transplant/Methodist Hospital, San Antonio
Texas Transplant/St David's South Austin, Austin
Colorado Blood Cancer Institute, Denver
Lead Sponsor
Mana Therapeutics
INDUSTRY